Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Soleo Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This post-hoc analysis assessed the double-blind, placebo-controlled 24-week Phase 3 study of edaravone, including an additional 24-week open-label period with all patients receiving IV edaravone.
Product Name : Radicava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Soleo Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Soleo Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Soleo Health's ability to collect specific data through its proprietary SoleMetrics patient outcomes program proved valuable in helping to elucidate real-world treatment patterns with IV edaravone in the U.S.
Product Name : Radicava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Soleo Health
Deal Size : Inapplicable
Deal Type : Inapplicable